Olema Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 74
- Market Cap
- $668.8M
- Website
- http://www.olema.com
Study of OP-3136 in Advanced or Metastatic Solid Tumors
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06784193
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸University Medical Center - New Orleans, New Orleans, Louisiana, United States
🇺🇸START - Midwest, Grand Rapids, Michigan, United States
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Conditions
- Metastatic Breast CancerHER2 Negative Breast CarcinomaBreast CancerAdvanced Breast CancerER Positive Breast Cancer
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06016738
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
🇲🇾Clinical Trials Site, Sungai Petani, Kedah, Malaysia
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
- Conditions
- Metastatic Breast CancerAdvanced Breast CancerER-positive Breast CancerHER2-negative Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT05508906
- Locations
- 🇺🇸
Advent Health Hematology and Oncology, Orlando, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05266105
- Locations
- 🇦🇺
Site 6101, Clayton, Victoria, Australia
🇦🇺Site 6102, South Brisbane, Queensland, Australia
🇦🇺Site 6109, Southport, Queensland, Australia
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
- Conditions
- Hormone Receptor Positive Breast CarcinomaHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT04505826
- Locations
- 🇺🇸
University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, Florida, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇦🇺Macquarie University, Sydney, New South Wales, Australia